-
The 2021 "Nobel Prize in Pharmaceutical Industry" officially announced that these products are on the list!
Time of Update: 2021-12-09
Best Biotechnology Product Award: Oxbryta (voxelotor), Global Blood TherapeuticsOxbryta is the first FDA-approved innovative therapy that targets the hemoglobin polymerization process and represents an innovative mechanism of action for the treatment of sickle cell anemia (SCD) .
-
LH-1802 Capsules of Lianhuan Pharmaceutical obtained the "Notice of Drug Clinical Trial Approval"
Time of Update: 2021-12-09
On November 9, Lianhuan Pharmaceutical issued an announcement stating that it had recently received the "Drug Clinical Trial Approval Notice" for LH-1802 capsules (specification: 0.
Recently, clinical trials of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been carried out .
-
The latest procurement progress and clinical use proportions of 157 nationally sourced varieties are at a glance!
Time of Update: 2021-12-09
From December 20, 2020 to September 30, 2021, the procurement situation is as follows:Purchase quantity and amountThe total number of selected drugs purchased in the 12 alliance regions of the province is 470,964,800 pieces/piece/bag .
-
Hengrui Medicine's new generation AR inhibitor listing application plans to be reviewed first!
Time of Update: 2021-12-09
Article source: Medical Rubik's Cube InfoAuthor: Shi BeiOn October 28, the CDE official website showed that the listing application of Hengrui SHR3680 tablets was planned to be included in the priority review and started to be publicized for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high tumor burden .
-
Suzhou Ruibo Biotechnology Co., Ltd. uses ArisGlobal's LifeSphere® MultiVigilance solution to improve its clinical trial data management
Time of Update: 2021-12-09
Ruibo Bio will use the Chinese and English versions of ArisGlobal's LifeSphere Multivigilance to manage its drug safety data and meet the regulatory requirements for its products to enter the clinical trial phase .
-
Kangtai Biological dual carrier 13-valent pneumonia vaccine is approved for marketing by NMPA
Time of Update: 2021-12-09
According to the press release, the vaccine is the world's first dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine, which uses two carrier proteins (tetanus toxoid/diphtheria toxoid) combined with pneumococcal capsular polysaccharide, which is different from single-carrier pneumococcal polysaccharides.
-
PI3Kδ inhibitor has been granted priority review by FDA Cinda Biotech owns rights and interests in Greater China
Time of Update: 2021-12-09
Retrieved November 1, 2021, from https:// Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas.
-
It works in 15 minutes and lasts for 6 hours!
Time of Update: 2021-12-09
Retrieved October 29, 2021, from https:// New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition.
Retrieved July 25, 2021, from https:// releases/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a-potential-novel-treatment-for-presbyopia-a-common-and-progressive-eye- condition-301339937.
com/news-releases/us-food-and-drug-administration-approves-vuity-pilocarpine-hci-ophthalmic-solution-1-25-the-first-and-only-eye-drop-to-treat -presbyopia-age-related-blurry-near-vision-301412259.
-
New IL-36 receptor monoclonal antibody takes a critical step in EU listing, and also submits marketing application in China
Time of Update: 2021-12-09
On October 29th, Boehringer Ingelheim announced that the European Medicines Agency (EMA) has accepted an application for marketing authorization (MAA) for the interleukin-36 receptor (IL-36R) inhibitor spesolimab for treatment Onset of generalized pustular psoriasis (GPP) .
-
Lepu Bio-PD-1 declared the second indication: MSI-H solid tumor
Time of Update: 2021-12-09
Author: ArmstrongOn October 26, 2021, the listing application of Lepu Bio's PD-1 monoclonal antibody Pritlizumab (HX008) for the treatment of MSI-H/dMMR solid tumors was accepted by NMPA, which is the second adaptation of the product declaration Disease .
-
The first patient was administered to the first patient in the clinical trial of the pioneering pharmaceutical industry's ALK-1 monoclonal antibody combined with Corning Jereh KN046 in the treatment of advanced or refractory solid tumors
Time of Update: 2021-12-09
ALK-1 monoclonal antibody combination therapy is in Taiwan, China The clinical trial data of the second-line treatment of advanced liver cancer showed that it has good safety and anti-tumor activity.
-
Genetron Health and NeoGenomics reached a strategic cooperation to help global oncology drug research and development
Time of Update: 2021-12-09
This cooperation, combined with the advantages of Xinjihao's global pharmaceutical services and clinical trials, and Genetron Health's experience in the localization of global innovative drugs, will help both parties to comprehensively improve their drug R&D support and service capabilities, and enable the company to better serve To meet the needs of global drug research and development and clinical projects .
-
The seventh batch of nationally picked these varieties has met the conditions
Time of Update: 2021-12-09
The size of irinotecan hydrochloride injection in the terminal market of China's public medical institutions in 2020 is 700 million yuan .
The increase in the number of cancer patients has promoted the rapid development of China's anti-tumor drug market .
-
Baekje BGB-16673 clinical trial application based on the innovative PROTAC technology platform was accepted by CDE
Time of Update: 2021-12-09
FinishingrainbowToday, the latest announcement by CDE shows that the clinical trial application of BeiGene BTK protein degradation agent BGB-16673 film-coated tablets has been accepted .
This is BeiGene's first product under development based on its protein-degrading CDAC (innovative PROTAC) platform and entering the clinical stage.
-
First-line treatment prolongs the lives of patients with biliary tract cancer. The combination of PD-L1 inhibitors is better than standard chemotherapy
Time of Update: 2021-12-09
On October 25, 2021, AstraZeneca announced that the blockbuster PD-L1 inhibitor durvalumab (durvalumab, English trade name: Imfinzi) was combined with chemotherapy for the first-line treatment of advanced biliary tract cancer ( BTC) patients reached the primary endpoint in a phase 3 clinical trial .
-
Potential curative therapy for hepatitis B has entered a critical development stage, and the virus can continue to be suppressed after the drug is stopped
Time of Update: 2021-12-09
Moreover, early clinical trial results showed that after 28 days of ATI-2173 medication, even if the medication is stopped, the patient's HBV DNA level can maintain a long time without rebound .
Reference materials:[1] Antios Therapeutics Raises $75 Million in a Series B-1 Funding to Advance Clinical Programs for HBV.
-
Deck Pharmaceuticals obtained US FDA approval of ATG-101 (PD-L1/4-1BB double antibody) for the treatment of solid tumors and non-Hodgkin's lymphoma Phase I trial of new drug research application
Time of Update: 2021-12-09
The approval of the IND enables Deqi Pharmaceuticals to initiate this phase I clinical study, which aims to evaluate the safety and tolerability of ATG-101 in patients with advanced solid tumors and non-Hodgkin's lymphoma .
-
Saisheng Pharmaceutical's Miconazole Oral Patch Nomico® is officially launched commercially
Time of Update: 2021-12-09
Nomico® is a miconazole patch with a unique patented dosage form, which can be quickly released in the oral cavity and maintain a stable antibacterial concentration to treat oropharyngeal candidiasis, once a day, providing patients with a new convenient treatment option .
-
Bayer meets its rivals!
Time of Update: 2021-12-09
According to data from Mi Nei. com, in 2020, the total sales of nifedipine tablets in the terminals of Chinese public medical institutions and the terminals of physical pharmacies in Chinese cities will exceed 8 billion yuan, of which Bayer has the largest market share .
-
3 billion large varieties were looted, Guangzhou pharmaceutical companies are about to be approved
Time of Update: 2021-12-09
com, lansoprazole will be the TOP5 drug for peptic ulcer treatment in public medical institutions in China in 2020, with sales exceeding 3 billion yuan .
